A U.S. Food and Drug Administration advisory panel is meeting on July 23 and 24 to review whether seven popular peptides should be made available through licensed compounding pharmacies, a decision that could reshape the regulatory landscape for substances that have surged in popularity despite limited clinical evidenc...